Application 063313
- Type
- ANDA
- Sponsor
- WEST-WARD PHARMS INT
Application Products#
| Product | Drug | Ingredient | Form | Strength | Reference drug | Reference standard |
|---|---|---|---|---|---|---|
| 001 | AMIKACIN SULFATE | AMIKACIN SULFATE | INJECTABLE;INJECTION | EQ 50MG BASE/ML | No | Yes |
Orange Book products#
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| A063313-001 | AMIKACIN SULFATE | AMIKACIN SULFATE | EQ 50MG BASE/ML | INJECTABLE / INJECTION | RS | 1994-04-11 |
Observed Orange Book product history#
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2022-10-28 04:53 UTC | 2022-10 | A063313-001 | AMIKACIN SULFATE | EQ 50MG BASE/ML | INJECTABLE / INJECTION | AP | RS | 1994-04-11 | f41ea6bd6efb… |
| 2022-09-29 23:25 UTC | 2022-09 | A063313-001 | AMIKACIN SULFATE | EQ 50MG BASE/ML | INJECTABLE / INJECTION | AP | RS | 1994-04-11 | e64feba35796… |
| 2022-07-09 03:26 UTC · 3 captures of this ZIP | 2022-07 | A063313-001 | AMIKACIN SULFATE | EQ 50MG BASE/ML | INJECTABLE / INJECTION | AP | RS | 1994-04-11 | cb3db0bc1861… |
| 2026-07-26 02:55 UTC · 3 captures of this ZIP | 2026-06 | A063313-001 | AMIKACIN SULFATE | EQ 50MG BASE/ML | INJECTABLE / INJECTION | RS | 1994-04-11 | a50c72e98297… |
Observed Orange Book normalized TE history#
| Captured | Edition | Application-product | TE code | Order | Source SHA-256 |
|---|---|---|---|---|---|
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | A063313-001 | AP | 1 | 5c6f7cd8ea54… |
| 2022-04-08 23:34 UTC | 2022-04 | A063313-001 | AP | 1 | 5d02ea3f76ae… |
| 2022-04-04 05:41 UTC | 2022-04 | A063313-001 | AP | 1 | 4b0b4de00fa7… |
| 2019-12-13 00:20 UTC | 2019-12 | A063313-001 | AP | 1 | 74a2ff9319b5… |
| 2022-03-09 01:35 UTC | 2022-03 | A063313-001 | AP | 1 | bb7c543d1eb4… |
| 2021-12-28 21:50 UTC | 2021-12 | A063313-001 | AP | 1 | 782e0a99824c… |
| 2021-05-05 16:15 UTC · 3 captures of this ZIP | 2021-05 | A063313-001 | AP | 1 | 87673890dc5c… |
| 2021-03-12 10:30 UTC | 2021-03 | A063313-001 | AP | 1 | 5aa47cf7b7d7… |
| 2020-12-22 03:56 UTC | 2020-12 | A063313-001 | AP | 1 | 8869cabd3fbd… |
| 2020-11-12 02:37 UTC | 2020-11 | A063313-001 | AP | 1 | c0c555d07b60… |
| 2019-12-14 00:12 UTC | 2019-12 | A063313-001 | AP | 1 | 3f01610625f2… |
| 2019-09-15 20:21 UTC | 2019-09 | A063313-001 | AP | 1 | b00525d2431f… |
| 2019-07-19 19:46 UTC | 2019-07 | A063313-001 | AP | 1 | ea99ee380514… |
| 2023-01-26 05:58 UTC | 2023-01 | A063313-001 | AP | 1 | 3bdfa0b2c4d7… |
| 2022-11-12 20:34 UTC · 5 captures of this ZIP | 2022-11 | A063313-001 | AP | 1 | 3a93d1ddd44b… |
| 2022-10-28 04:53 UTC | 2022-10 | A063313-001 | AP | 1 | f41ea6bd6efb… |
| 2022-09-29 23:25 UTC | 2022-09 | A063313-001 | AP | 1 | e64feba35796… |
| 2022-07-09 03:26 UTC · 3 captures of this ZIP | 2022-07 | A063313-001 | AP | 1 | cb3db0bc1861… |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| amikacin sulfate | AMIKACIN SULFATE | Sagent Pharmaceuticals | f260ff2a-76a0-4672-9516-91c344b67890 | 2026-07-27 | Boxed warning, Warnings, Adverse reactions | amikacin sulfate AMIKACIN SULFATE |
| Amikacin Sulfate | AMIKACIN SULFATE | Mullan Pharmaceutical Inc. | 840ba25a-d60c-4f0d-a084-71b0c68237df | 2026-01-13 | Boxed warning, Warnings, Adverse reactions | Amikacin Sulfate AMIKACIN SULFATE |
| Amikacin Sulfate | AMIKACIN SULFATE | Qilu Pharmaceutical Co., Ltd. | 20fa61ef-11e2-4d01-82ea-b5412cefaead | 2025-12-10 | Boxed warning, Warnings, Adverse reactions | Amikacin Sulfate AMIKACIN SULFATE |
| Amikacin Sulfate | AMIKACIN SULFATE | Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc. | a43188fa-f228-4acd-8a5d-9a3462034f4b | 2025-06-18 | Boxed warning, Warnings, Adverse reactions | Amikacin Sulfate AMIKACIN SULFATE |
| Amikacin Sulfate | AMIKACIN SULFATE | Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc. | 7791d3e1-9287-4f75-b4f0-e5d35cacfd6e | 2024-06-28 | Boxed warning, Warnings, Adverse reactions | Amikacin Sulfate AMIKACIN SULFATE |
| Amikacin Sulfate | AMIKACIN SULFATE | Hikma Pharmaceuticals USA Inc. | 0b56f6df-a05d-4520-8bf0-d7cefe20f6ad | 2024-04-08 | Boxed warning, Warnings, Adverse reactions | Amikacin Sulfate AMIKACIN SULFATE |
| Amikacin Sulfate | AMIKACIN SULFATE | Fresenius Kabi USA, LLC | c0f57839-1c9b-49e5-8c7a-708e2d16495d | 2023-05-31 | Boxed warning, Warnings, Adverse reactions | Amikacin Sulfate AMIKACIN SULFATE |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.